Fusion inhibitors are a new class of antiretroviral drugs (ARVs) for the treatment of human
immunodeficiency virus infection. Enfuvirtide is the first in this class to reach market …

The envelope glycoprotein complex (Env) is responsible for entry of the human
immunodeficiency virus type 1 (HIV-1) into cells by mediating attachment to target cells and …

The objective of this study was to track the evolution of sequence changes in both the
heptad region 1 (HR1) and HR2 domains of gp41 associated with resistance to enfuvirtide …

Background: Enfuvirtide (ENF) is the first of a novel class of drugs that block HIV gp41-
mediated viral fusion to host cells. Viruses with mutations at positions 36–38 in HIV-1 gp41 …

Mutations in GJB2 (gap junction protein, beta-2) are the major cause of autosomal recessive
non-syndromic hearing loss. A few allele variants of this gene also cause autosomal …

The fusion inhibitor T20 belongs to a new class of anti-human immunodeficiency virus type 1
(HIV-1) drugs designed to block entry of the virus into the host cell. However, the success of …

Background: Drug resistance continues to be a major challenge in the treatment of HIV-1
infection. Virtually all currently available antiretroviral medications inhibit the viral reverse …

Enfuvirtide (Fuzeon®), a fusion inhibitor, is indicated in combination with other antiretroviral
agents in the treatment of HIV infection in treatment-experienced adults and children aged> …

Entry inhibitors of human immunodeficiency virus, type 1 (HIV-1) have been the focus of
much recent research. C34, a potent fusion inhibitor derived from the HR2 region of gp41 …

Current therapeutic intervention in HIV infection relies upon 20 different drugs. Despite the
impressive efficacy shown by these drugs, we are confronted with an unexpected frequency …